Overview

The information below is intended only to provide the recommendations from the Committee to Evaluate Drugs (CED)  and decisions by the Executive Officer regarding:

  • the listing of products on the Formulary
  • funding of cancer drugs through the New Drug Funding Program (NDFP)
  • funding through the Exceptional Access Program (EAP)
  • funding through the Special Drugs Program (SDP)
The information on this site is intended for information purposes only and does not constitute medical advice. For information on prescription drugs, please consult a qualified healthcare professional.

The CED reviews select drugs for public funding in Ontario.  The Executive Officer (EO), Ontario Public Drug Programs, seeks the committee’s advice in making final funding decisions. Please note that the specific drugs (for example, specific drug identification numbers [DINs]) reviewed by the Canadian Agency for Drugs and Technologies of Health (CADTH) Common Drug Review process are not subsequently assessed by this committee .

EO decisions and CED recommendations